Using an engineered protein to dissect pharmacological signaling of CXCR4 we have extended our initial discovery of partial agonism in pancreas cancer cells to a high-risk hematologic malignancy to examine how agonists of the same receptor function. The gene discussed is CXCR4; the disease is pancreatic neoplasm.